Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study

Michael Martin, John S. Welch, Jingqin Luo, Matthew J. Ellis, Timothy A. Graubert, Matthew J. Walter

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The aim of this study was to determine the association between age and stage at diagnosis of breast cancer with the subsequent development of acute myeloid leukemia (AML). The National Cancer Institute's Surveillance, Epidemiology, and End Results program were analyzed for incidence of second malignancies by age and stage at diagnosis of breast cancer. 420,076 female patients were identified. There was an age dependent risk of a subsequent diagnosis of AML in women younger than 50 years old (RR 4.14; P < 0.001) and women 50-64 years old (RR 2.19; P < 0.001), but not those 65 and older (RR 1.19; P = 0.123) when compared with the expected incidence of AML. A similar age dependent pattern was observed for second breast and ovarian cancers. There was also a stage dependent increase in risk of subsequent AML in younger women with stage III disease when compared with stage I disease (RR 2.92; P = 0.004), and to a lesser extent in middle age women (RR 2.24; P = 0.029), but not in older women (RR 0.79; P = 0.80).Younger age and stage III disease at the time of breast cancer diagnosis are associated with increased risk of a subsequent diagnosis of AML. This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalBreast Cancer Research and Treatment
Volume118
Issue number3
DOIs
StatePublished - Dec 1 2009

Fingerprint

Acute Myeloid Leukemia
Survivors
Breast Neoplasms
Second Primary Neoplasms
Population
SEER Program
Therapeutics
National Cancer Institute (U.S.)
Incidence
Genetic Predisposition to Disease
Ovarian Neoplasms
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. / Martin, Michael; Welch, John S.; Luo, Jingqin; Ellis, Matthew J.; Graubert, Timothy A.; Walter, Matthew J.

In: Breast Cancer Research and Treatment, Vol. 118, No. 3, 01.12.2009, p. 593-598.

Research output: Contribution to journalArticle

Martin, Michael ; Welch, John S. ; Luo, Jingqin ; Ellis, Matthew J. ; Graubert, Timothy A. ; Walter, Matthew J. / Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. In: Breast Cancer Research and Treatment. 2009 ; Vol. 118, No. 3. pp. 593-598.
@article{b437202e05d2456ea9e146bf2675846f,
title = "Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study",
abstract = "The aim of this study was to determine the association between age and stage at diagnosis of breast cancer with the subsequent development of acute myeloid leukemia (AML). The National Cancer Institute's Surveillance, Epidemiology, and End Results program were analyzed for incidence of second malignancies by age and stage at diagnosis of breast cancer. 420,076 female patients were identified. There was an age dependent risk of a subsequent diagnosis of AML in women younger than 50 years old (RR 4.14; P < 0.001) and women 50-64 years old (RR 2.19; P < 0.001), but not those 65 and older (RR 1.19; P = 0.123) when compared with the expected incidence of AML. A similar age dependent pattern was observed for second breast and ovarian cancers. There was also a stage dependent increase in risk of subsequent AML in younger women with stage III disease when compared with stage I disease (RR 2.92; P = 0.004), and to a lesser extent in middle age women (RR 2.24; P = 0.029), but not in older women (RR 0.79; P = 0.80).Younger age and stage III disease at the time of breast cancer diagnosis are associated with increased risk of a subsequent diagnosis of AML. This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition.",
author = "Michael Martin and Welch, {John S.} and Jingqin Luo and Ellis, {Matthew J.} and Graubert, {Timothy A.} and Walter, {Matthew J.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s10549-009-0376-3",
language = "English (US)",
volume = "118",
pages = "593--598",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study

AU - Martin, Michael

AU - Welch, John S.

AU - Luo, Jingqin

AU - Ellis, Matthew J.

AU - Graubert, Timothy A.

AU - Walter, Matthew J.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The aim of this study was to determine the association between age and stage at diagnosis of breast cancer with the subsequent development of acute myeloid leukemia (AML). The National Cancer Institute's Surveillance, Epidemiology, and End Results program were analyzed for incidence of second malignancies by age and stage at diagnosis of breast cancer. 420,076 female patients were identified. There was an age dependent risk of a subsequent diagnosis of AML in women younger than 50 years old (RR 4.14; P < 0.001) and women 50-64 years old (RR 2.19; P < 0.001), but not those 65 and older (RR 1.19; P = 0.123) when compared with the expected incidence of AML. A similar age dependent pattern was observed for second breast and ovarian cancers. There was also a stage dependent increase in risk of subsequent AML in younger women with stage III disease when compared with stage I disease (RR 2.92; P = 0.004), and to a lesser extent in middle age women (RR 2.24; P = 0.029), but not in older women (RR 0.79; P = 0.80).Younger age and stage III disease at the time of breast cancer diagnosis are associated with increased risk of a subsequent diagnosis of AML. This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition.

AB - The aim of this study was to determine the association between age and stage at diagnosis of breast cancer with the subsequent development of acute myeloid leukemia (AML). The National Cancer Institute's Surveillance, Epidemiology, and End Results program were analyzed for incidence of second malignancies by age and stage at diagnosis of breast cancer. 420,076 female patients were identified. There was an age dependent risk of a subsequent diagnosis of AML in women younger than 50 years old (RR 4.14; P < 0.001) and women 50-64 years old (RR 2.19; P < 0.001), but not those 65 and older (RR 1.19; P = 0.123) when compared with the expected incidence of AML. A similar age dependent pattern was observed for second breast and ovarian cancers. There was also a stage dependent increase in risk of subsequent AML in younger women with stage III disease when compared with stage I disease (RR 2.92; P = 0.004), and to a lesser extent in middle age women (RR 2.24; P = 0.029), but not in older women (RR 0.79; P = 0.80).Younger age and stage III disease at the time of breast cancer diagnosis are associated with increased risk of a subsequent diagnosis of AML. This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition.

UR - http://www.scopus.com/inward/record.url?scp=70449556603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449556603&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0376-3

DO - 10.1007/s10549-009-0376-3

M3 - Article

VL - 118

SP - 593

EP - 598

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -